EGCG inhibits the nuclear factor-κB signalling pathway. (A) Expression levels of phosphorylated and unphosphorylated IκBα and p65 determined by western blot analysis on days 1, 3, 7, 14 and 28 after modelling. (B) Expression levels of phosphorylated and unphosphorylated IκBα and p65 determined by western blot analysis in the control group, model group, and groups treated with EGCG for 14 and 28 days. ***P<0.001 EGCG, epigallocatechin-3-gallate; p-, phosphorylated-.